MCID: ESN008
MIFTS: 55

Eosinophilic Pneumonia

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Pneumonia

MalaCards integrated aliases for Eosinophilic Pneumonia:

Name: Eosinophilic Pneumonia 12 15 17 74
Pneumonia, Eosinophilic 12 77 54
Pulmonary Eosinophilia 45 74
Pulmonary Infiltrates with Eosinophilia 54
Asthmatic Pulmonary Eosinophilia 74
Simple Pulmonary Eosinophilia 74
Pneumonia Eosinophilic 56
Loeffler Syndrome 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5870
MeSH 45 D011657
NCIt 51 C35150
SNOMED-CT 69 91053000
ICD10 34 J82

Summaries for Eosinophilic Pneumonia

Disease Ontology : 12 A pneumonia in which certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. It is caused by certain medications or environmental triggers, parasitic infections, and cancer. The most common symptoms include cough, fever, difficulty breathing, and sweating at night.

MalaCards based summary : Eosinophilic Pneumonia, also known as pneumonia, eosinophilic, is related to chronic eosinophilic pneumonia and pulmonary eosinophilia, and has symptoms including hemoptysis and coughing. An important gene associated with Eosinophilic Pneumonia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Eosinophilic pneumonia is a disease in which an eosinophil, a type of white blood cell, accumulates in... more...

Related Diseases for Eosinophilic Pneumonia

Diseases in the Eosinophilic Pneumonia family:

Chronic Eosinophilic Pneumonia

Diseases related to Eosinophilic Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 34.0 CCL11 CCL5 IL5 RNASE3
2 pulmonary eosinophilia 32.4 CCL11 CCL17 CCL5 IL13 IL5 RNASE3
3 ascaris lumbricoides infection 31.7 IL13 IL5
4 pneumonia 30.8 CCL11 CCL5 IL13 IL5 SFTPD
5 churg-strauss syndrome 30.2 CCL17 IL5 RNASE3
6 allergic bronchopulmonary aspergillosis 30.0 CCL17 IL5 SFTPD
7 aspergillosis 29.8 CCL17 CSF2 IL5 SFTPD
8 folliculitis 29.8 CCL11 CCL5 IL5
9 gastroenteritis 29.7 CCL11 IL5 RNASE3
10 interstitial lung disease 29.7 CCL17 CCL5 SFTPD
11 bronchitis 29.6 CCL11 IL5 RNASE3
12 bullous pemphigoid 29.6 CCL11 IL5 RNASE3
13 bronchiolitis 29.2 CCL11 CCL5 IL13 IL5 RNASE3
14 schistosomiasis 29.2 IL13 IL5 RNASE3
15 eosinophilic gastroenteritis 29.1 CCL11 IL3 IL5 RNASE3
16 allergic asthma 28.7 CCL11 CCL17 CCL5 IL13 IL5 RNASE3
17 pulmonary disease, chronic obstructive 28.5 CCL11 CCL5 IL13 RNASE3 SFTPD
18 hypereosinophilic syndrome 28.4 CCL11 CCL17 CSF2 IL13 IL3 IL5
19 lung disease 28.4 CCL5 CSF2 IL13 IL5 RNASE3 SFTPD
20 asthma 27.8 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
21 allergic hypersensitivity disease 27.7 CCL11 CCL17 CCL22 CCL5 IL13 IL3
22 idiopathic acute eosinophilic pneumonia 12.7
23 loeffler syndrome 11.2
24 pemphigoid gestationis 10.3 CCL11 IL5
25 respiratory failure 10.3
26 chronic meningitis 10.3 CCL11 IL5
27 vulvovaginitis 10.3 CCL11 CCL5
28 loeffler endocarditis 10.2 IL5 RNASE3
29 arthritis 10.2
30 palladium allergic contact dermatitis 10.2 CCL17 CSF2
31 cough variant asthma 10.2 IL5 RNASE3
32 cow milk allergy 10.2 IL5 RNASE3
33 milk allergy 10.2 IL5 RNASE3
34 inclusion conjunctivitis 10.2 CCL5 IL5
35 rheumatoid arthritis 10.2
36 sinusitis 10.2 IL5 RNASE3
37 blepharoconjunctivitis 10.2 CCL11 RNASE3
38 eosinophilic granulomatosis with polyangiitis 10.1
39 maxillary sinusitis 10.1 CCL5 RNASE3
40 giant papillary conjunctivitis 10.1 CCL11 RNASE3
41 bullous skin disease 10.1 CCL5 IL5
42 allergic angiitis 10.1
43 acute cervicitis 10.1 CCL5 CSF2
44 hypereosinophilic syndrome, idiopathic 10.1 IL3 IL5
45 filariasis 10.1
46 necatoriasis 10.1 CCL17 CCL22 IL5
47 wells syndrome 10.1 IL5 RNASE3
48 contact dermatitis 10.1 CCL17 CCL22 IL5
49 lymphoma 10.1
50 toxocariasis 10.1

Graphical network of the top 20 diseases related to Eosinophilic Pneumonia:



Diseases related to Eosinophilic Pneumonia

Symptoms & Phenotypes for Eosinophilic Pneumonia

UMLS symptoms related to Eosinophilic Pneumonia:


hemoptysis, coughing

MGI Mouse Phenotypes related to Eosinophilic Pneumonia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCL11 CCL17 CCL5 CSF2 IL13 IL5
2 immune system MP:0005387 9.56 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
3 respiratory system MP:0005388 9.02 CCL11 CSF2 IL13 IL5 SFTPD

Drugs & Therapeutics for Eosinophilic Pneumonia

Drugs for Eosinophilic Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
6
Omalizumab Approved, Investigational Phase 4,Phase 2 242138-07-4
7
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
9 Reslizumab Approved, Investigational Phase 4,Phase 3,Phase 2
10
Budesonide Approved Phase 4 51333-22-3 5281004 63006
11 Benralizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1044511-01-4
12
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
13 Hormone Antagonists Phase 4,Phase 2,Phase 3
14 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
15 Prednisolone acetate Phase 4,Phase 3
16 Neuroprotective Agents Phase 4
17 glucocorticoids Phase 4,Phase 2,Phase 3
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
19 Peripheral Nervous System Agents Phase 4,Phase 2
20 Antiemetics Phase 4
21 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
22 Gastrointestinal Agents Phase 4
23 Protective Agents Phase 4
24 Methylprednisolone Acetate Phase 4,Phase 3
25 Hormones Phase 4,Phase 2,Phase 3
26 Autonomic Agents Phase 4,Phase 2
27 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
28 Immunologic Factors Phase 4,Phase 2,Phase 3
29 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
30 Tocolytic Agents Phase 4,Phase 2
31 Adrenergic Agents Phase 4,Phase 2
32 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Not Applicable
33 Adrenergic beta-Agonists Phase 4,Phase 2
34 Adrenergic Agonists Phase 4,Phase 2
35 Bronchodilator Agents Phase 4,Phase 2
36 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Neurotransmitter Agents Phase 4,Phase 2
38 Anti-Allergic Agents Phase 4,Phase 2
39 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
41 Albuterol Phase 4,Phase 2
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
43 Radiopharmaceuticals Phase 4
44 Fluorodeoxyglucose F18 Phase 4
45
Sodium Citrate Approved, Investigational Phase 3 68-04-2
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
47 Immunoglobulin G Phase 3
48 Antineoplastic Agents, Immunological Phase 2, Phase 3
49 Citrate Phase 3
50
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
3 Small Particle Steroids in Refractory Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
4 Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma Recruiting NCT03610685 Phase 4 Prednisolone;Placebo oral capsule
5 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Recruiting NCT03034005 Phase 4 Budesonide
6 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
7 Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatic (CHINOOK) Not yet recruiting NCT03953300 Phase 4
8 An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation Terminated NCT02937168 Phase 4 Reslizumab;Fludeoxyglucose F 18 (FDG);Placebo
9 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
10 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
11 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
12 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
13 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
14 Study of Mepolizumab Autoinjector in Asthmatics Completed NCT03099096 Phase 3 Mepolizumab
15 Study of Mepolizumab Safety Syringe in Asthmatics Completed NCT03021304 Phase 3 Mepolizumab
16 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
17 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Completed NCT02135692 Phase 3 SOC
18 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
19 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
20 Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Recruiting NCT03557307 Phase 3
21 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Active, not recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
22 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
23 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
24 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
25 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
26 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
27 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Completed NCT02560610 Phase 2 OC000459;Placebo
28 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
29 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Completed NCT02377427 Phase 2 Mepolizumab
30 Effect of Benralizumab in Atopic Dermatitis Recruiting NCT03563066 Phase 2 Benralizumab;Placebo Control
31 Pregnancy Rate, Asthma, Infertility, Omalizumab Recruiting NCT03727971 Phase 2 Omalizumab Injection;NaCl
32 GB001 in Adult Subjects With Moderate to Severe Asthma Recruiting NCT03683576 Phase 2 GB001;Placebo Oral Tablet
33 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia Unknown status NCT01152424
34 Intense Airway Eosinophilia in Asthma Completed NCT03696914
35 Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma Completed NCT03453021 Mepolizumab
36 Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center Completed NCT03209934
37 Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
38 A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
39 Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Recruiting NCT03733535 Not Applicable Benralizumab;129 Xenon
40 Exploring Asthma Exacerbations in Mepolizumab Treated Patients Recruiting NCT03324230
41 BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS) Recruiting NCT03925415
42 Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab Recruiting NCT03369574 Reslizumab
43 Real-world Daptomycin Use in Chinese ICUs Recruiting NCT03588637
44 European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Recruiting NCT02852928
45 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
46 Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma Active, not recruiting NCT03563521
47 Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland Not yet recruiting NCT03907137
48 Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients Not yet recruiting NCT03931954

Search NIH Clinical Center for Eosinophilic Pneumonia

Cochrane evidence based reviews: pulmonary eosinophilia

Genetic Tests for Eosinophilic Pneumonia

Anatomical Context for Eosinophilic Pneumonia

MalaCards organs/tissues related to Eosinophilic Pneumonia:

42
Lung, Testes, Bone, T Cells, Breast, Skin, Bone Marrow

Publications for Eosinophilic Pneumonia

Articles related to Eosinophilic Pneumonia:

(show top 50) (show all 565)
# Title Authors Year
1
Allergic bronchopulmonary aspergillosis in succession to chronic eosinophilic pneumonia. ( 30670338 )
2019
2
Anti-interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis. ( 30574332 )
2019
3
Traction bronchiectasis on high-resolution computed tomography may predict fatal acute eosinophilic pneumonia. ( 30528687 )
2019
4
Chronic eosinophilic pneumonia after trastuzumab and radiation therapy for breast cancer: A case report. ( 30608451 )
2019
5
Chronic eosinophilic pneumonia: clinical perspectives. ( 30936702 )
2019
6
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis. ( 31030460 )
2019
7
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient. ( 30461210 )
2019
8
Heat-not-burn cigarettes induce fulminant acute eosinophilic pneumonia requiring extracorporeal membrane oxygenation. ( 30560050 )
2019
9
Elevated Periostin Concentrations in the Bronchoalveolar Lavage Fluid of Patients with Eosinophilic Pneumonia. ( 30612125 )
2019
10
Age distribution and seasonality in acute eosinophilic pneumonia: analysis using a national inpatient database. ( 30755187 )
2019
11
Acute Eosinophilic Pneumonia Induced by Varnish Particles: A Diagnostic Challenge. ( 30785104 )
2019
12
Cigarette smoking-induced acute eosinophilic pneumonia: A case report. ( 30817609 )
2019
13
Acute eosinophilic pneumonia following electronic cigarette use. ( 30963023 )
2019
14
Acute eosinophilic pneumonia triggered by secondhand cigarette smoke exposure in an elderly man. ( 30968672 )
2019
15
Elevated levels of periostin and TGF-β1 in the bronchoalveolar lavage fluid of patients with idiopathic eosinophilic pneumonia. ( 31012597 )
2019
16
Extracorporeal Membrane Oxygenation in Severe Acute Eosinophilic Pneumonia. ( 31024915 )
2019
17
Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient. ( 31050015 )
2019
18
Diagnostic pitfalls of acute eosinophilic pneumonia in an adolescent boy following cigarette smoking: A case report. ( 31096462 )
2019
19
Pulmonary Actinomycosis in a Patient with Chronic Eosinophilic Pneumonia treated with Omalizumab. ( 28720253 )
2018
20
Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia. ( 30395734 )
2018
21
Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: A review of the previous literature. ( 29395966 )
2018
22
Conjunctival Eosinophilic Masses With Chronic Eosinophilic Pneumonia. ( 30044249 )
2018
23
Elevated Levels of Intelectin-1, a Pathogen-binding Lectin, in the BAL Fluid of Patients with Chronic Eosinophilic Pneumonia and Hypersensitivity Pneumonitis. ( 30101907 )
2018
24
A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. ( 30201098 )
2018
25
Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia. ( 30444149 )
2018
26
Chronic Eosinophilic Pneumonia with Cardiac Involvement. ( 30627188 )
2018
27
The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome. ( 29093389 )
2018
28
Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature. ( 29093391 )
2018
29
Two patients with daptomycin induced eosinophilic pneumonia with different presentations and treatment. ( 29201637 )
2018
30
Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management. ( 29206477 )
2018
31
Drug-induced eosinophilic pneumonia: A review of 196 case reports. ( 29369189 )
2018
32
A case of cocaine-induced eosinophilic pneumonia: Case report and review of the literature. ( 29487790 )
2018
33
Acute eosinophilic pneumonia in the deployed military setting. ( 29605194 )
2018
34
Sertraline-Induced Acute Eosinophilic Pneumonia. ( 29607784 )
2018
35
A recurrent case of eosinophilic pneumonia with high IL-25 levels. ( 29779833 )
2018
36
Eosinophilic pneumonia induced by non-steroidal anti-inflammatory drugs: An underestimated risk. ( 29789133 )
2018
37
Daptomycin eosinophilic pneumonia: an adverse effect to be aware of. ( 29791122 )
2018
38
Risperidone-Associated Acute Eosinophilic Pneumonia. ( 29889675 )
2018
39
Acute eosinophilic pneumonia associated with smoking: a case report. ( 29915648 )
2018
40
Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses. ( 29915657 )
2018
41
Acute eosinophilic pneumonia with periferic alveolar infiltrates. ( 30144934 )
2018
42
Indeterminate dendritic cell neoplasm accompanied by eosinophilic pneumonia successfully treated by systemic steroid therapy: Report of the first case with muscular and parotid involvement and review of published work. ( 30320463 )
2018
43
Daptomycin-induced Acute Eosinophilic Pneumonia. ( 30397557 )
2018
44
Acute Eosinophilic Pneumonia due to Piperacillin/Tazobactam. ( 30552984 )
2018
45
Pneumocystis jirovecii pneumonia in an HIV-infected patient mimicking acute eosinophilic pneumonia: a case report with a review of the literature. ( 30622810 )
2018
46
Eosinophilic pneumonia: remember topical drugs as a potential etiology. ( 30726330 )
2018
47
BILATERAL CENTRAL RETINAL VEIN OCCLUSIONS IN A YOUNG PATIENT WITH A HISTORY OF EOSINOPHILIC PNEUMONIA AND THALAMIC STROKE. ( 28045864 )
2018
48
Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids. ( 28626631 )
2017
49
Chronic Eosinophilic Pneumonia: A Diagnostic Challenge. ( 28694046 )
2017
50
Chronic eosinophilic pneumonia after radiation therapy for squamous cell lung cancer. ( 28831373 )
2017

Variations for Eosinophilic Pneumonia

Expression for Eosinophilic Pneumonia

Search GEO for disease gene expression data for Eosinophilic Pneumonia.

Pathways for Eosinophilic Pneumonia

Pathways related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CCL11 CCL22 CCL5 CSF2 IL13 IL3
2
Show member pathways
13.64 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
3
Show member pathways
13.48 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
4
Show member pathways
13.33 CCL11 CCL17 CCL22 CCL5 IL13 IL3
5
Show member pathways
13.23 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
6
Show member pathways
13.16 CCL11 CCL22 CCL5 CSF2 IL13 IL3
7
Show member pathways
13.1 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
8
Show member pathways
12.72 CCL11 IL13 IL3 IL5 RNASE3
9
Show member pathways
12.7 CCL11 CCL17 CCL22 CCL5
10
Show member pathways
12.44 CSF2 IL13 IL3 IL5
11
Show member pathways
12.26 CSF2 IL13 IL3 IL5
12
Show member pathways
12.23 CCL11 CCL17 CSF2 IL13 IL5
13
Show member pathways
12.05 CCL11 CCL17 CCL22 CCL5
14
Show member pathways
12 CSF2 IL3 IL5
15
Show member pathways
11.89 CCL11 CCL17 CCL22 CCL5
16
Show member pathways
11.88 CCL11 CCL17 CCL22 CCL5 IL13 IL3
17 11.87 CSF2 IL3 IL5
18 11.86 CCL11 CCL22 IL13
19 11.78 CSF2 IL3 IL5
20 11.69 CSF2 IL13 IL5
21
Show member pathways
11.65 CSF2 IL3 IL5
22 11.57 CCL11 CCL5 CSF2 IL13 IL5
23 11.55 CCL11 CCL17 IL5
24 11.45 CCL22 CCL5 CSF2 IL13
25 11.42 CSF2 IL3 IL5
26 11.32 CCL11 CCL17 CCL22 IL13 IL5
27 11.28 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
28 11.17 CSF2 IL13 IL3 IL5
29 11.16 IL13 IL5
30 11.07 IL13 IL5
31 10.66 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
32 10.46 CCL11 CCL17 CCL22 CCL5 CSF2 IL13

GO Terms for Eosinophilic Pneumonia

Cellular components related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
2 extracellular space GO:0005615 9.32 CCL11 CCL17 CCL22 CCL5 CSF2 IL13

Biological processes related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.88 CCL11 CCL17 CCL22 CCL5
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 CCL11 CCL17 CCL22 CCL5
3 cell-cell signaling GO:0007267 9.86 CCL17 CCL22 CCL5 IL3
4 MAPK cascade GO:0000165 9.85 CCL5 CSF2 IL3 IL5
5 inflammatory response GO:0006954 9.85 CCL11 CCL17 CCL22 CCL5 IL13 IL5
6 chemotaxis GO:0006935 9.84 CCL11 CCL17 CCL22 CCL5
7 cellular response to tumor necrosis factor GO:0071356 9.83 CCL11 CCL17 CCL22 CCL5
8 cellular response to interferon-gamma GO:0071346 9.8 CCL11 CCL17 CCL22 CCL5
9 neutrophil chemotaxis GO:0030593 9.78 CCL11 CCL17 CCL22 CCL5
10 response to virus GO:0009615 9.77 CCL11 CCL22 CCL5
11 cellular response to interleukin-1 GO:0071347 9.76 CCL11 CCL17 CCL22 CCL5
12 chemokine-mediated signaling pathway GO:0070098 9.73 CCL11 CCL17 CCL22 CCL5
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CCL5 CSF2 IL13 IL3
14 cytokine-mediated signaling pathway GO:0019221 9.7 CCL11 CCL22 CCL5 CSF2 IL13 IL3
15 eosinophil chemotaxis GO:0048245 9.69 CCL11 CCL22 CCL5
16 positive regulation of B cell proliferation GO:0030890 9.62 IL13 IL5
17 monocyte chemotaxis GO:0002548 9.62 CCL11 CCL17 CCL22 CCL5
18 positive regulation of JAK-STAT cascade GO:0046427 9.61 CCL5 IL5
19 macrophage chemotaxis GO:0048246 9.61 CCL5 SFTPD
20 positive regulation of podosome assembly GO:0071803 9.6 CSF2 IL5
21 induction of bacterial agglutination GO:0043152 9.58 RNASE3 SFTPD
22 lymphocyte chemotaxis GO:0048247 9.56 CCL11 CCL17 CCL22 CCL5
23 immune response GO:0006955 9.56 CCL11 CCL17 CCL22 CCL5 CSF2 IL13
24 regulation of signaling receptor activity GO:0010469 9.23 CCL11 CCL17 CCL22 CCL5 CSF2 IL13

Molecular functions related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 CSF2 IL3 IL5
2 chemokine activity GO:0008009 9.46 CCL11 CCL17 CCL22 CCL5
3 lipopolysaccharide binding GO:0001530 9.37 RNASE3 SFTPD
4 CCR4 chemokine receptor binding GO:0031729 9.26 CCL17 CCL5
5 CCR chemokine receptor binding GO:0048020 9.26 CCL11 CCL17 CCL22 CCL5
6 cytokine activity GO:0005125 9.23 CCL11 CCL17 CCL22 CCL5 CSF2 IL13

Sources for Eosinophilic Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....